Skip Navigation

Annals of Oncology 2009 20(Supplement 7):vii1-vii6; doi:10.1093/annonc/mdp281
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verslype, C.
Right arrow Articles by van de Velde, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verslype, C.
Right arrow Articles by van de Velde, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Annals of Oncology issue: ESMO Conference: 11th World Congress on Gastrointestinal Cancer 24-27 June, 2009: Barcelona, Spain [View the issue table of contents]

symposium article

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008

C. Verslype1, E. Van Cutsem1,*, M. Dicato2, N. Arber3, J. D. Berlin4, D. Cunningham5, A. De Gramont6, E. Diaz-Rubio7, M. Ducreux8, T. Gruenberger9, D. Haller10, K. Haustermans11, P. Hoff12, D. Kerr13, R. Labianca14, M. Moore15, B. Nordlinger16, A. Ohtsu17, P. Rougier16, W. Scheithauer18, H.-J. Schmoll19, A. Sobrero20, J. Tabernero21 and C. van de Velde22

1 Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
2 Department of Haematology-Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg
3 Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv, Israel
4 Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
5 Department of Medical Oncology, The Royal Marsden Hospital, Surrey, UK
6 Medical Oncology, Saint Antoine Hospital, Paris, France
7 Department of Medical Oncology, San Carlos Hospital Clinic, Madrid, Spain
8 Department of Medical Oncology, Institut Gustave-Roussy, Villejuif, France
9 Department of Surgery, Hepatobiliary Service, Medical University Vienna, Vienna, Austria
10 Abramson Cancer Center at the University of Pennsylvania, Philadelphia, USA
11 Department of Radiotherapy, University Hospital Gasthuisberg, Leuven, Belgium
12 Department of Gastrointestinal Medical Oncology, Hospital Sirio-Libanes, Sao Paulo, Brazil
13 Department of Clinical Pharmacology, University of Oxford, Oxford, UK
14 Medical Oncology Unit, Ospedale Riuniti, Bergamo, Italy
15 Division of Applied Molecular Oncology, University of Toronto, Toronto, Ontario, Canada
16 Departments of Surgery and Gastroenterology, Hôpital Ambroise Paré, Boulogne, France
17 Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
18 Department of Internal Medicine I and Cancer Center, Medical University Vienna, Vienna, Austria
19 Department of Hematology and Oncology, Martin Luther Universität, Halle, Germany
20 Medical Oncology, San Martino Hospital, Genova, Italy
21 Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
22 Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

* Correspondence to: Prof. Dr E. Van Cutsem, Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. Tel: +32-16-344225; Fax: +32-16-344419; E-mail: eric.vancutsem{at}uz.kuleuven.ac.be

This article summarizes the expert discussion on the management of hepatocellular carcinoma (HCC), which took place during the 10th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, June 2008. A multidisciplinary approach to a patient with HCC is essential, to guarantee optimal diagnosis and staging, planning of surgical options and selection of embolisation strategies or systemic therapies. In many patients, the underlying cirrhosis represents a challenge and determines therapeutic options. There is now robust evidence in favour of systemic therapy with sorafenib in patients with advanced HCC with preserved liver function. Those involved in the care for patients with HCC should be encouraged to participate in well-designed clinical trials, to increase evidence-based knowledge and to make further progress.

Key words: hepatocellular carcinoma, liver transplantation, chemoembolisation, sorafenib


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
K. Lacombe, J. Bottero, M. Lemoine, A. Boyd, and P. M. Girard
HIV/hepatitis B virus co-infection: current challenges and new strategies
J. Antimicrob. Chemother., January 1, 2010; 65(1): 10 - 17.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.